Department of Medicine 3 – Rheumatology and Immunology

Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys (2022) Naveen R, Joshi M, Sen P, Agarwal V, Shinjo S, Kardes S, Lilleker JB, et al. Conference contribution COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis (2022) Naveen R, Parodis I, Joshi M, Sen P, Kim M, Agarwal V, Kardes S, et al. Conference contribution COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution 3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) - Data from the RELIANCE Registry (2022) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Schuetz C, Kallinich T, et al. Conference contribution How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? - Exploratory Results from a Phase 3b Study (2022) D'Agostino MA, Conaghan PG, Gaillez C, Naredo E, Mandl P, Carron P, Senolt L, et al. Conference contribution A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information (2022) Gräf M, Knitza J, Leipe J, Krusche M, Welcker M, Kuhn S, Mucke J, et al. Conference contribution Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male - Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial (2022) Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Rech J, Burmester G, et al. Conference contribution Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naive Adults with PsA (2022) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty S, et al. Conference contribution Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast (2022) Mease PJ, Gladman D, Schett G, Paris M, Cheng S, Richter S, Teng L, Kavanaugh A Conference contribution